The Effect of Oral Levamisole Co-administration on the Level of Immune Response to Hepatitis B Vaccine in Healthy Individuals: A Randomized Clinical Trial
-
Mousalreza Hosseini
,
Payman Shalchiantabrizi
,
Maliheh Dadgarmoghaddam
,
Saeideh Ahmady-Simab
,
Azizollah Behjati
,
Masoumeh Salari
Abstract
Despite its proven efficacy, the hepatitis B vaccine requires improvements in immune enhancement and durability, especially in the elderly. Levamisole, an immune modulator, has been tested as an adjuvant to hepatitis B vaccine in several studies in immune-compromised populations. However, we aimed to evaluate the effect of levamisole on the immune response to hepatitis B vaccine in healthy subjects. In this randomized clinical trial, healthy family members of chronic hepatitis B patients were given twenty-microgram intramuscular injections of hepatitis B vaccine at 0, 1, and 6 months and 50 miligrams of oral levamisole twice a day for two weeks with every vaccination dose. Serum hepatitis B surface antibody (HBsAb) levels of ultimately 98 individuals were measured one month after the final vaccination dose and compared to those of 119 subjects that received placebo and vaccine with an identical regimen. HBsAb levels >10 mIU/mL were considered protective. The Student’s t-test, Mann-Whitney test, Kruskal–Wallis analysis (quantitative comparison in age groups), Chi-square test, and the Pearson correlation were used to analyze data. p<0.05 was considered significant. Serum HBsAb levels were significantly higher in the test group (p<0.001). All test subjects had levels above 50 mIU/mL (86.7% exceeding 100 mIU/mL). The quantitative response according to age groups was remarkable (p=0.01 and p<0.001 for placebo and levamisole, respectively), while that of gender was insignificant (p=0.9). Unlike HBsAb titers amongst controls, levels in the levamisole group were affected by smoking (p=0.79 and p=0.006, respectively). We conclude that oral levamisole as an adjuvant to the hepatitis B vaccine enhances the anti-HBs antibody in healthy vaccinees.
1. Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 2003; 6(2):106-12.
2. Kalantari H, Davari M, Akbari M, Hejazi SM, Kalantari M, Zakerin S, et al. The estimation of direct medical costs of treating patients with chronic hepatitis B and C in iran. Int J Prev Med 2012; 3(3):191-6.
3. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49(5 Suppl):S28-34.
4. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci 2009; 14(4):249-58.
5. Agarwal N, Naik S, Aggarwal R, Singh H, Somani SK, Kini D, et al. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J Gastroenterol 2003; 22(4):127-31.
6. Center for Diseases Control and Prevention. Washington: Center for Diseases Control and Prevention; date unknown [updated 2001 Apr 21; cited 2014 Aug 2] Available fromhttp://www.cdc.gov/mmwr/preview/mmwrhtml.
class="Default">7. Zhang W, Du X, Zhao G, Jin H, Kang Y, Xiao C, et al. Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination. Vaccine 2009; 27(36):4938-46.
8. Chen LY, Lin YL, Chiang BL. Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol 2008; 151(1):174-81.
9. Sayad B, Alavian SM, Najafi F, Soltani B, Shirvani M, Janbakhsh A, et al. Effects of Oral Levamisole as an Adjuvant to Hepatitis B Vaccine in HIV/ AIDS Patients: A Randomized Controlled Trial. Hepat Mon 2012; 12(9):e6234.
10. Sanadgol H, Khoshnoodi M, Mashhadi MA, Forghani MS. Effect of adding levamisole on seroconversion response to hepatitis B virus vaccination in hemodialysis patients: a single-center experience. Iran J Kidney Dis 2011; 5(5):338-41.
11. Sali S, Alavian SM, Hajarizadeh B. Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology (Carlton) 2008; 13(5):376-9.
12. Alavian SM, Tabatabaei SV. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials. Clin Ther 2010; 32(1):1-10.
13. Argani H, Akhtarishojaie E. Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patients. J Immune Based Ther Vaccines 2006; 30(4):3.
14. Kayataş M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Organs 2002; 26(6):492-6.
15. Chang A, Osterloh J, Thomas J. Levamisole: a dangerous new cocaine adulterant. Clin Pharmacol Ther 2010; 88(3):408-11.
16. Wolford A, McDonald TS, Eng H, Hansel S, Chen Y, Bauman J, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. Drug Metab Dispos 2012; 40(6):1067-75.
17. Hepatitis B foundation: cause for a cure [Internet]. Pennsylvania: Hepatitis B Foundation. 2003 (updated 2009; cited 2014 July 29]. Available from: http://www.hepb.org/professionals/vaccine_non-responders.htm.
class="Default">18. Kardar GA, Jeddi-Tehrani M, Shokri F. Diminished Th1 and Th2 cytokine production in healthy adult: nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 2002; 55(3):311-4.
19. Shokrgozar MA, Shokri F. Antibody Response to Recombinant Hepatitis B Surface Antigen in Healthy Adults Following Primary and Supplementary Vaccination. Iran J Med Sci 2001; 26(1-2):10-5.
20. Janbakhsh A, Sayad B, Vaziri S, Aieni P.Serologic response to hepatitis B vaccine in health care workers, Kermanshah, Iran. J Res Med Sci 2005; 10(3):147-9.
21. Zamani F, Fallahian F, Hashemi F, Shamsaei Z, Alavian SM. Immune response to hepatitis B vaccine in health-care workers. Saudi J Kidney Dis Transpl 2011; 22(1):179-84.
22. Fitzsimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Longterm efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23(32):4158-66.
23. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, et al.Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 321(11):708-12.
24. Sjogren MH.Prevention of hepatitis B in nonresponders to initial hepatitis B virus vaccination. Am J Med 2005; 118(Suppl 10A):34S-39S.
25. Soroosh P, Shokri F, Azizi M, Jeddi-Tehrani M. Analysis of T-cell receptor beta chain variable gene segment usage in healthy adult responders and nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 2003; 57(5):423-31.
26. Platkov E, Shlyakhov E, Glick V, Khalemsky S, Fischbein A. Humoral immune response of hospital employees induced by a recombinant hepatitis b vaccine: 5 years after the primary standard immunization. J Prev Med 2001; 9(3):59-66.
27. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. Centers for Disease Control and Prevention. Washington: Centers for Disease Control and Prevention; date unknown [updated 2006 nov 21; cited 2014 August 4] vailable from:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a1htm?s_cid=rr5516a1_e#top.
class="Default">28. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000; 355(9203):561-5.
29. Coursaget P, Leboulleux D, Soumare M, le Cann P, Yvonnet B, Chiron JP, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994; 21(2):250-4.
30. Da Villa G, Pelliccia MG, Peluso F, Ricciardi E, Sepe A. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol 1997; 148(2):109-14.
31. Looney RJ, Hasan MS, Coffin D, Campbell D, Falsey AR, Kolassa J, et al. Hepatitis B immunization of healthy elderly adults: relationship between naïve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol 2001; 21(1):30-6.
32. Ibrahim S, el-Din S, Bazzal I. Antibody level after hepatitis-B vaccination in hemodialysis patients: impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status. J Natl Med Assoc 2006; 98(12):1953-7.
33. Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl 2014; 25(1):185-91.
34. Schillie S, Murphy TV, Sawyer M, Ly K, Hughes E, Jiles R, et al. Center for Diseases Control and Prevention. Washington: Center for Diseases Control and Prevention; date unknown [updated 2001 Apr 21; cited 2014 Aug 10]. Available from:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6210a1.htm.
class="Default">35. Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994; 12(9):771-2.
36. Shaw FE Jr, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7(5):425-30.
| Files | ||
| Issue | Vol 16, No 3 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Immunization Hepatitis B vaccines Levamisole | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
